Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 18;371(25):2383-93.
doi: 10.1056/NEJMoa1409065. Epub 2014 Nov 18.

HDL cholesterol efflux capacity and incident cardiovascular events

Anand Rohatgi  1 , Amit Khera, Jarett D Berry, Edward G Givens, Colby R Ayers, Kyle E Wedin, Ian J Neeland, Ivan S Yuhanna, Daniel R Rader, James A de Lemos, Philip W Shaul
Affiliations

HDL cholesterol efflux capacity and incident cardiovascular events

Anand Rohatgi et al. N Engl J Med. .

Abstract

Background: It is unclear whether high-density lipoprotein (HDL) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport. We investigated the epidemiology of cholesterol efflux capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a large, multiethnic population cohort.

Methods: We measured HDL cholesterol level, HDL particle concentration, and cholesterol efflux capacity at baseline in 2924 adults free from cardiovascular disease who were participants in the Dallas Heart Study, a probability-based population sample. The primary end point was atherosclerotic cardiovascular disease, defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization or death from cardiovascular causes. The median follow-up period was 9.4 years.

Results: In contrast to HDL cholesterol level, which was associated with multiple traditional risk factors and metabolic variables, cholesterol efflux capacity had minimal association with these factors. Baseline HDL cholesterol level was not associated with cardiovascular events in an adjusted analysis (hazard ratio, 1.08; 95% confidence interval [CI], 0.59 to 1.99). In a fully adjusted model that included traditional risk factors, HDL cholesterol level, and HDL particle concentration, there was a 67% reduction in cardiovascular risk in the highest quartile of cholesterol efflux capacity versus the lowest quartile (hazard ratio, 0.33; 95% CI, 0.19 to 0.55). Adding cholesterol efflux capacity to traditional risk factors was associated with improvement in discrimination and reclassification indexes.

Conclusions: Cholesterol efflux capacity, a new biomarker that characterizes a key step in reverse cholesterol transport, was inversely associated with the incidence of cardiovascular events in a population-based cohort. (Funded by the Donald W. Reynolds Foundation and others.).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Atherosclerotic Cardiovascular Disease Events, According to Models Based on High-Density Lipoprotein (HDL) Cholesterol Level and Cholesterol Efflux Capacity
Hazard ratios and 95% confidence intervals (CIs), derived from Cox proportional-hazards models, are shown for the comparisons of quartile 4 (highest) with quartile 1 (lowest) of cholesterol efflux capacity. A total of 132 participants had a primary end-point event of atherosclerotic cardiovascular disease, defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization (percutaneous coronary intervention or coronary-artery bypass grafting) or death from cardiovascular causes. Traditional risk factors included age, sex, race, presence or absence of diabetes, presence or absence of hypertension, status with regard to current smoking, body-mass index, total cholesterol level, log-transformed triglyceride level, and status with regard to a history of statin use.
Figure 2
Figure 2. Kaplan–Meier Curves and Hazard Ratios for Cardiovascular Events, According to Quartile of Cholesterol Efflux Capacity
Kaplan–Meier curves and hazard ratios and 95% confidence intervals are shown for quartiles (Q1 through Q4) of cholesterol efflux capacity, with the use of quartile 1 (lowest cholesterol efflux capacity) as the reference, derived from Cox proportional-hazards models. Each quartile had equal numbers of men and women, and equal numbers of blacks and nonblacks. A total of 132 participants had a primary end-point event of atherosclerotic cardiovascular disease (Panel A), and 172 had a secondary end-point event of total cardiovascular disease (Panel B). Total cardiovascular disease was defined as the composite of the end points related to atherosclerotic cardiovascular disease and peripheral revascularization or hospitalization for heart failure or atrial fibrillation. Adjusted models included traditional risk factors for atherosclerotic cardiovascular disease, HDL cholesterol level, and HDL particle concentration. The insets show the same data on enlarged y axes.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(Suppl 2):S1–S45. Erratum, Circulation 2014;129:Suppl 2:S46–S48. - PubMed
    1. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. Erratum, N Engl J Med 2012;367:189. - PubMed
    1. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22. - PubMed
    1. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99. - PubMed
    1. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12. - PubMed

Publication types